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Abstract 
Skeletal muscle tissue is a rare site of tumor metastasis but is the main target of the 
degenerative processes occurring in cancer-associated cachexia syndrome. Beneficial effects 
of physical activity in counteracting cancer-related muscle wasting have been described in the 
last decades. Recently it has been shown that, in tumor xeno-transplanted mouse models, 
physical activity is able to directly affect tumor growth by modulating inflammatory responses 
in the tumor mass microenvironment. Here, we investigated the effect of physical activity on 
tumor cell growth in colon carcinoma C26 cells injected tibialis anterior muscles of BALB/c 
mice. Histological analyses revealed that 4 days of voluntary wheel running significantly 
counteracts tumor cell growth in C26-injected muscles compared to the non-injected sedentary 
controls. Since striated skeletal muscle tissue is the site of voluntary contraction, our results 
confirm that physical activity can also directly counteract tumor cell growth in a metabolically 
active tissue that is usually not a target for metastasis. 
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 Cancer cachexia is a multifactorial catabolic syndrome 
associated with tumor progression.
1
 It is characterized by 
progressive muscle degeneration mediated by an 
imbalance between protein synthesis and protein 
degradation in favor of an increased rate of skeletal 
muscle proteolysis.
2-4
 This chronic wasting condition is 
mainly sustained by high levels of circulating pro-
inflammatory cytokines and tumor-released factors (e.g. 
interleukins 1β and 6 (IL1β, IL6), tumor necrosis factor 
alpha (TNF-α) and proteolysis inducing factor (PIF)), 
which specifically trigger the proteolysis of muscle 
proteins.
5
 To date, no specific cures exist for cancer 
cachexia and the pharmacological strategies commonly 
adopted aim to treat the cancer itself, rather than 
targeting degenerative molecular mechanisms at the 
muscle site.
4
 
Recently, there is an emerging interest in the possible 
effects of physical activity on the incidence, prognosis 
and treatment of cancer.
6-8
 A wide range of beneficial 
effects mediated by physical exercise in cancer cachexia 
have been reported in both murine
9
 and human 
studies.
7,8,10
 Epidemiological studies showed that 
physical activity has a pivotal role in reducing tumor 
incidence,
6,11
 improving responsiveness to 
chemotherapy
8
 and, in general, ameliorating cancer 
patients’ quality of life.11-13 In this view, physical 
exercise has been proposed as an adjuvant therapy in 
cancer, including breast
11,14
 and colon cancers.
11
  
At the molecular level, physical exercise has been 
identified as a key modulator of systemic 
inflammation
12
, able to counteract muscle atrophy by 
restoring the physiological autophagic flux, to decrease 
muscle proteolysis and to preserve muscle mass and 
function in both cancer patients
7,8,10,12,13,15
 and tumor-
bearing mice.
9,16
  A recent report described a causal 
relationship between physical activity and tumor 
growth inhibition.
17
 Pedersen et al.
17
  showed that 
voluntary running suppresses tumor growth by 
remodeling the inflammatory background in the tumor 
microenvironment in several tumor models. 
Specifically, high circulating epinephrine levels due to 
voluntary running increase NK cell tumor infiltration 
which in turn impairs tumor growth. Although many 
studies address the beneficial effects of physical 
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exercise at multi-organ and multi-systemic levels,
18
 it is 
still not clear why skeletal muscle tissue, which is a main 
tissue target of pathophysiological changes occurring in 
cancer cachexia,
2,5
 is refractory to tumor cell 
colonization and metastasis.
19-21
 
Here, we performed histological analyses of tibialis 
anterior (TA) muscles from mice injected with colon 
carcinoma C26 cells to test the effects of physical 
activity on tumor cell growth specifically at the 
contraction site. Our results showed a significant 
reduction of tumor cell growth in muscles from 
physically active mice compared with the sedentary 
ones. These data confirm the ability of physical exercise 
to counteract tumor cell growth. 
Materials and Methods 
Mice 
Nine 8-weeks-old male BALB/c mice were used for this 
study. To study the effects of physical activity on tumor 
cell growth, 1x10
4
 murine colon carcinoma C26 cells 
were re-suspended in PBS (50µl) and injected in tibialis 
anterior (TA) muscles. TA from the contralateral leg 
was injected with the same volume of PBS as control in 
each mouse. Mice were housed in standard conditions 
with day/night cycles of 12 hours, received water and 
food ad libitum, and were euthanized 4 days after tumor 
injection.  
All the mice used in this study were treated in 
accordance with ARRIVE guidelines and following the 
three R’s rule of Replacement, Reduction and 
Refinement principles.
22
 Protocols adopted in the study 
have been approved by the animal experimentation 
ethics committee of KU Leuven, Belgium. 
Exercise protocol 
Mice were randomly assigned to three experimental 
groups: (i) C26-injected mice hosted in standard cages 
(sedentary control group, C26 REST), (ii) non-injected 
running mice hosted in wheel-equipped cages (running 
control group, Ctr WR) and (iii) C26-injected running 
mice hosted in wheel-equipped cages (C26 WR). 
Cages were prepared as previously described.
23
 Briefly, 
one cage per mouse was used and all wheels were 
supplied with a cycle computer in order to record 
physical activity data (i.e. daily distance, total distance, 
average and maximum speed and time spent on the 
wheel). Mice in the running groups were hosted in 
wheel-equipped cages starting from the day before 
tumor cell injection, to familiarize the animals with the 
use of the new environmental stimulus (i.e. wheel) 
until the day of sacrifice (4 days after tumor cells 
injection). 
Histology  
TA muscles were dissected, weighed, embedded in 
tissue freezing medium (Leica, Wetzlar, GE), frozen in 
liquid nitrogen-cooled isopentane and stored at -80ºC.  
Muscle cryosections of 7 μm thickness were obtained 
using a cryostat (Leica Biosystems). For histological 
analysis, the sections were stained with Hematoxylin 
and Eosin (H&E, Sigma-Aldrich) using a standard 
method. 
Table 1. Physical activity. Values are means ± SEM of 3 independent experiments per group 
 
 Total DST 
(Km) 
Speed at day 4 (Km/h) Average of total time 
(hh:mm:ss) 
Average Max 
Ctr WR 18.06 ± 3.52 1.3 ± 0.07 2.5 ± 0.09 15:57:47 ± 02:17:12 
C26 WR 19.55 ± 2.60 1.4 ± 0.06 2.5 ± 0.04 14:55:29 ± 01:54:17 
 
 
Fig 1. Voluntary wheel running exercise. (A) Mice from running groups were hosted in wheel-equipped cages. (B) 
non-injected running mice (Ctr WR) and C26-injected running mice (C26 WR) covered comparable daily 
distance until the end of experiment, 4 days. Data are means ± SEM of 3 independent experiments. 
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Immunofluorescence 
Transverse cryosections were fixed in 4% 
paraformaldehyde for 10 min at room temperature (RT) 
and permeabilized in 1% bovine serum albumin 
(BSA)/0.2% Triton in Phosphate-Buffered Saline 
solution (PBS) for 30 min. After incubation with 1% 
BSA in PBS (30 min), samples were incubated with a 
goat polyclonal anti-Ki67 Ab (Sc-78, Santa Cruz) (1:100 
in BSA), followed by incubation with anti-goat Alexa 
fluor 488 conjugated Ab (Molecular Probes, Eugene, 
OR) (1:500 in BSA). Macrophage staining: samples 
were incubated with a rat anti-mouse F4/80 (Bio Rad 
MCA 497G), followed by incubation with anti-mouse 
Alexa fluor 594 conjugated Ab (Molecular Probes, 
Eugene, OR). IgG-immunostaining was performed by 
incubation with anti-mouse Alexa fluor 594 conjugated 
Ab (Molecular Probes, Eugene, OR) (1:500 in BSA) for 
45 min at RT. Nuclei were stained for 5 min with 0.5 
μg/ml Hoechst 33342 (Sigma). 
Morphometric analysis 
Morphometric analysis was performed on pictures from 
H&E staining. Three different cross-sectional areas of 
each muscle were analyzed. Muscle and tumor areas 
were calculated as relative percentages. ImageJ 
Software (National Institutes of Health, Bethesda, MD, 
USA) was used to perform this analysis.  
Statistics 
All quantitative data are presented as mean ± standard 
error of mean (SEM) of three independent 
experiments. Statistical analysis was performed using 
Student’s t-test or one-way and two-way ANOVA 
followed by Bonferroni post-hoc testing using 
GraphPad Prism 5 software (GraphPad Software, San 
Diego, CA). A p-value less than 0.05 was considered 
to be statistically significant. 
Results 
Voluntary running activity showed no significant 
differences in terms of daily distance, total distance, 
average running speed and total running time (Fig. 1 B 
and Table 1) between non-injected and C26-injected 
mice. These data indicate that the amount of tumor 
cells injected in the muscles did not affect voluntary 
physical activity of the mice. 
By histological analyses we evaluated the effects of 
Table 2. Body and muscle weight. 
 
 Body weight (BW) Muscle weight/BW (mg/gr) 
Initial Final C26 PBS 
C26 REST 26.47 ± 0.97 25.13 ± 1.04 2.96 ± 0.06* 2.38 ± 0.03 
C26 WR 24.93 ± 0.29 23.17 ± 0.27 2.67 ± 0.11 2.43 ± 0.09 
Values are means ± SEM of 3 independent experiments per group.  
TA C26 REST versus TA PBS REST: *p < 0.05 by 1way ANOVA. 
 
Fig 2.  Size and muscle weight analyses. (A) In C26 REST mice (B1.4, B1.5 and B1.6) C26-injected TA muscles appear to 
be larger than the contralateral PBS-injected muscles compared with those derived from C26 WR (B1.1, B1.2 and 
B1.3). Dashed yellow lines help the comparisons. (B) Muscle weight analysis confirmed the differences observed in 
(A). Error bars are shown as means ± SEM of 3 independent experiments; ** p = 0.01 by 2way ANOVA. 
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physical activity on tumor growth 4 days after tumor cell 
injection in TA muscles from mice at rest and under 
voluntary running conditions. Since the study was 
performed using a small number of animals per 
experimental group (n = 3), we tracked samples from 
every mouse in order to display the consistency of the 
 
Fig 3.  Histological features of areas containing tumor cells in C26-injected muscles. C26-injected muscles from mice 
at rest and running conditions developed tumor areas characterized by a high number of cells/area. Tumor 
cells had bigger nuclei (yellow arrowheads), compared with the infiltrating cells observed in the tumor areas 
(yellow arrows) or myonuclei (white arrows). Right up and down panels represents magnification areas from 
yellow rectangles of left panels. Bars: bottom left = 100 μm, bottom right = 200 μm. 
 
 
 
Fig 4. H&E staining of C26-injected muscles. (A) H&E staining of representative transverse cryosections 
obtained by photomicrographs reconstruction. Dashed black lines represents areas of tumor cell growth. 
(B) Morphometric analysis of tumor cell growth. Bar = 0.5 mm. Error bars are shown as means ± SEM of 3 
independent experiments. 
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results. Specifically, mice from the sedentary injected-
group (C26 REST) are indicated in the figures as B1.4, 
B1.5, B1.6, while mice from voluntary running injected-
group (C26 WR) are indicated as B1.1, B1.2, and B1.3, 
according with the experimental recording system 
adopted in our laboratory. At the end-point (sacrifice 
day), C26-injected muscles from mice at rest were bigger 
than the PBS-injected contralateral ones, while no 
significant differences were found between C26 and 
PBS-injected muscles from the exercised group (Fig. 2 
A). Muscle weight analysis confirmed these findings (p 
< 0.01, Fig. 2 B, table 2).  
Next, by H&E staining, we identified areas containing 
tumor cells in C26-injected muscles (Fig. 3 A and 4 
A). Regions containing tumor cells were characterized 
by a high number of cells per area. Tumor cells had 
larger nuclei compared to the myonuclei and 
mononuclear cells observed in the tumor areas, as 
 
Fig 5.  Tumor cell growth in C26-injected muscles. (A) Representative images of tumor cell growth areas. Green, Ki-
67 positive nuclei, dashed yellow lines represent muscle fibers, blue Hoechst.  (B) Tumor cll growth analysis. 
Error bars are shown as means ± SEM of 3 independent experiments; *p < 0.05 compared with Student’s t-test.  
 
 
Fig 6.  Inflammatory background. (A) Representative images of local inflammation in control and tumor cells-
injected muscles. Red, mouse IgG, blue Hoechst. Bar = 100 μm. (B) Spleen weight analysis between control, 
C26 REST and C26 WR mice. Error bars are shown as means ± SEM of 3 independent experiments. 
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shown in figure 3 A. Moreover, the staining for F4/80 
revealed only a limited amount of macrophage cells 
within the tumor areas (Fig. 3 B).  To investigate the 
nature of the differences in size and weight of injected 
muscles between non-exercised and running mice, we 
analyzed the tumor areas developed in muscles (Fig. 4 
A). Specifically, cross-sectional area (CSA) analysis of 
C26-injected muscles showed that tumor cells expanded 
at the site of injection. No single cells were found far 
from the side of injection (Fig. 3 A and 4 A).  
Morphometric analysis showed that in C26-injected 
muscles from sedentary mice the tumor cells represent 
7.9% ± 1.2 of the total muscle CSA, while in muscles 
from the C26-injected running group the average of 
tumor cells-covered area was 5.1% ± 1.3/CSA (Fig. 4 B). 
These results indicate a trend of reduced tumor growth in 
the running mice. Since tumor cells are characterized by 
high proliferative rates, we further investigated the 
effects of physical activity on tumor cell growth by 
analyzing the cells expressing Ki-67, a known marker of 
cellular proliferation (Fig. 5 A and B).
24
 This approach 
allowed us to better determine the extent and the impact 
of tumor cells growth in the muscle tissue, without the 
contribution of other cells (e.g. inflammatory infiltrate), 
which were limited compared to the number of tumor 
cells in C26-injected muscles (Fig. 3 B). Quantitative 
analysis of Ki-67 positive cells from tumor areas showed 
a significant reduction of tumor cell proliferation in 
muscles of running mice compared to those derived from 
sedentary mice (p < 0.05, Fig. 5 B).  
Because tumor development is normally associated with 
an inflammatory response in the target tissue, we also 
analyzed the inflammatory state of injected muscles (Fig. 
6). Immunoglobulin staining revealed a high 
inflammatory background in C26-injected muscles, 
while a basal level of IgG was found in both PBS-
injected and healthy control muscles (Fig. 6 A). These 
observations indicate that tumor cells induced local 
inflammation. Next, we measured the weight of the 
spleen, an organ sensitive to chronic inflammatory 
conditions including cancer. Quantitative analysis 
showed a comparable weight of the spleen between C26-
injected and non-injected mice (Fig. 6 B). These data, 
together with the analysis of body weight of non-
exercised tumor-injected mice, which showed no 
changes in body weight between the day of tumor cells 
injection and the end of experiment (Table 2), confirmed 
that tumor cells mediated at local level the muscle 
changes without any further contribution due to the 
presence of a chronic systemic inflammation. 
Discussion 
A general consensus has been reached in the last years 
concerning the beneficial effects of physical exercise in 
the prevention, management and treatment of chronic 
degenerative conditions,
6
 including cancer.
6,11,12
 
Currently, public health offices recommend regular 
physical exercise for a healthy lifestyle.
6
 
In cancer epidemiology, physical activity is associated 
with a reduced incidence, a better prognosis, an 
increased responsiveness to therapy and a general 
improvement in patients’ quality of life.11 These 
evidences result from clinical studies performed on 
specific tumor types, including breast, colon and 
pancreatic cancers.
11
 The effects of physical activity on 
tumor growth have long been debated.
25,26
 
Interestingly, a recent study showed that voluntary 
running exercise leads to a remodeling of immune cells 
colonizing the tumor microenvironment of tumor-
transplanted mice.
17
 In particular, researchers showed 
that physical activity negatively affects tumor growth 
by increasing the recruitment of NK cells within the 
tumor mass.
17
  
Skeletal muscle tissue is the main target of the 
pathophysiological changes occurring both in early,
27-29
 
and in advanced stages of cancer progression, such as 
loss of muscle mass and function.
30,31
 The elevated 
systemic inflammation originating from the tumor is a 
pivotal mediator of muscle wasting observed in cancer 
patients.
2
 The inflammation also affects other organs 
and tissues (e.g. fat tissue)
3
, a condition known as 
cancer cachexia syndrome. Thus, according to data 
reported in the literature, there is a strong correlation 
between tumor progression and immune response.
32-34
 
In this picture, the elevated inflammatory background 
can mask direct beneficial effects of physical activity 
on tumor cells growth and the molecular mechanisms 
involved. 
Here, we analyzed the direct effects of physical activity 
on tumor cell growth in a chronic systemic 
inflammation-independent context. Specifically, we 
adopted voluntary running as a form of exercise 
compatible with advanced stages of tumor progression, 
as emerged by clinical studies performed in cancer 
patients.
15
 We injected C26 colon carcinoma cells in 
TA muscles of BALB/c mice, to directly determine the 
effects of muscle contraction on their growth. 
Muscle is the most represented and metabolically 
active tissue in the body, and its capillary bed is 
certainly extremely extended. Thus, it could 
theoretically represent a suitable site for tumor 
development. However, clinical reports only rarely 
document events of tumor metastasis occurring in 
skeletal muscles. So far, tumor metastasis in muscle 
tissue have been reported only in a few cases of 
laryngeal squamous carcinoma,
35-37
 lung cancer,
38
 
papillary thyroid cancer,
39
 bladder cancer,
40
 and 
gastrointestinal stromal tumor.
41,42
 
Our data show that muscles injected with C26 cells 
develop tumor cells expansion after 4 days of cell 
implantation, suggesting that muscle tissue per se is a 
permissive environment for tumor cell growth. 
Histological analyses revealed that a total of ~15 hours 
of voluntary wheel running (table 1), which is 
considered a low-intensity
43,44
 and aerobic
12
 exercise, 
accumulated over a period of 4 days leads to a 
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significant reduction of tumor cell growth compared 
with muscles from sedentary mice. Interestingly, we 
injected tumor cells in muscles of healthy mice and 
samples were analyzed 4 days later, so the observed 
tumor cell growth was independent of the systemic 
inflammation usually reported after longer periods in 
tumor bearing mouse models. This aspect was confirmed 
by weight analysis of the spleen, that revealed no 
differences between healthy and C26 muscle-injected 
mice. On the contrary, an increased local inflammatory 
background was observed in C26-injected muscles from 
both sedentary and running mice, compared with non-
injected and PBS-injected muscles.  
Overall, our results indicate that, although the muscle 
microenvironment is generally unfavorable for growth of 
metastatic cancer cells, its refractoriness can be 
modulated by exercise.  
The observations of this study confirmed that physical 
activity acts as negative regulator for tumor cells growth 
in skeletal muscle tissue. However, further analyses are 
needed to better investigate the relationship between 
tumor-mediated local inflammation, tumor dissemination 
and physical activity. Whether the inflammatory, 
reparative and myoregenerative responses that may 
occur in muscle during wheel running
27-29,45-47
 may have 
direct effects on the metastatic processes remain to be 
investigated. 
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